NLRP3: From Scientific Curiosity to Therapeutic Efficacy

NLRP3 has been dubbed the "molecule du jour." Indeed, we have made significant strides in understanding the NLRP3 inflammasome and its role in numerous diseases. Dr. Rebecca C. Coll, Dr. Kate Schroder, and Dr. Pablo Pelegrín conducted a comprehensive review on the use of NLRP3 inflammasome and pyroptosis blockers to treat inflammatory diseases in Trends in Pharmacological Sciences. Viva In Vitro founder Dr. Pelegrín's research demonstrates that the NLRP3 inflammasome is crucial in the inflammatory response during sepsis, acting as an initiator of caspase-1 activation and pro-inflammatory cytokine production. Its activation serves as a prognostic marker to stratify patients and ensure early, appropriate treatment.

Scientific Advancements
Understanding the role of the canonical NLRP3 activation pathway has contributed to the development of new inflammasome and immunological therapies. By modulating P2X7 or inhibiting NLRP3, these therapies reduce mortality, improve patient conditions, or achieve these objectives without compromising the immune system or with fewer adverse effects. A notable case has been the development of the well-known inhibitor MCC950, which definitively established NLRP3 as a viable therapeutic target. However, we have yet to fully leverage the potential of detecting NLRP3 activation or closely associated markers like ASC-specks for diagnosis, prognosis, therapeutic stratification, and monitoring.

Clinical Impact
The fact that we are dealing with intracellular markers, requiring sample preparation for analysis, has been an objective hurdle. Another factor has been the shift in investment towards algorithms, which has been fruitful and convenient but has in some cases neglected the quality or sufficiency of the initial data (markers) used. For instance, applying better algorithms to detect the original infection that caused sepsis does not expand the limits of diagnosis, although it improves its outcome. We need to address the reasons why certain patients, after effectively treating the infection, severely worsen because sepsis led to an NLRP3 immunosuppression situation that was not treated. Similarly, in very different conditions, from neuropathies to certain leukemias, the response to treatment or the likelihood of a patient's condition worsening could be related to their NLRP3 activation levels, according to ongoing research.

Collaboration and Technology Transfer
Dr. Mihai Netea has succeeded in unraveling some of the complex relationships between innate immunity and epigenetics, as well as the role of NLRP3 in trained immunity. Applying his extraordinary ability to understand complex relationships in inflammasome biology, Dr. Netea has also performed admirable work within the biomedical innovation ecosystem in collaboration with corporations and hospitals, facilitating the transfer of this knowledge to broad clinical use, that is, to industry. Despite the extraordinary work of pioneers like Dr. Netea, success stories in a relatively close field such as immuno-oncology with the development of checkpoint inhibitors like Keytruda and others, and interesting initiatives like the COST Prestocomm action on P2X result translation or the previous EUCOR initiative on NLRP3, much remains to be done in terms of transfer and collaboration within the triangle composed of (i) hospitals and medical care companies, (ii) biotech startups and venture capital funds, and (iii) diagnostics and pharmaceutical corporations. The aging population, amongst other vectors, such as the imperative need to control healthcare spending, make the translation of inflammasome research to diagnostics more necessary and potentially more socially and financially profitable than ever.

Conclusion
The potential of NLRP3-based diagnostics and therapies is clear, but realizing this potential requires a concerted effort from all stakeholders. We must update our perceptions and approaches based on the latest scientific knowledge. The talent exists across hospitals, biotech startups, and established corporations to overcome the known obstacles. We've seen similar challenges surmounted in cell and gene therapies, and in the application of AI to healthcare. Now, we must apply that same innovative spirit to inflammasome diagnostics. As executives and investors in the biomedical field, we have a unique opportunity – and responsibility – to drive this paradigm shift. Let us pave the way for the next generation of personalized therapies. 
 

Joaquín Gómez Moya,
Executive President,
Viva In Vitro.